The authors declare that they have no competing interests.
KSP dietary management, drafting and reviewing the manuscript. RLR reviewed and drafted the manuscript. PMC dietary management and reviewing the manuscript. DJT data interpretation, drafting and reviewing the manuscript. All authors (KSP, DJT, RLR, PMC) read and approved the final manuscript.
Addison’s disease, or primary adrenal insufficiency, is often associated with reduced well-being and fatigue despite use of currently recommended adrenal hormone replacement. Hypoglycaemia is a known manifestation of glucocorticoid deficiency, but is generally considered rare in adults and not relevant to troubling ongoing symptoms in patients with Addison’s disease.
A 43 year old woman with a three year history of Addison’s disease complained of severe morning fatigue and headaches, despite standard glucocorticoid replacement therapy in the form of thrice daily hydrocortisone and mineralocorticoid replacement with fludrocortisone. Alternative glucocorticoid replacement regimens and the addition of dehydroepiandrosterone replacement therapy had no effect. Nocturnal hypoglycaemia was suspected and a 4-day continuous glucose monitor system (CGMS) revealed hypoglycaemia (interstitial glucose < 2.2 mmol/L) between 0200–0400 h on 3 of 4 days. The patient was counselled to take an evening snack designed to ensure slow absorption of ingested carbohydrates. Nocturnal hypoglycaemia was then absent on follow up CGMS assessment. The patient noted a marked symptomatic improvement in morning symptoms, but with persistent fatigue during the day.
Currently, the best strategy for control of non-specific symptoms in treated Addison’s disease is unknown, but it may be that investigation for hypoglycaemia and treatment, where necessary, could assist some sufferers to achieve improved wellbeing. A systematic study of this phenomenon in Addison’s disease is required.
Løvås K, Loge JH, Husebye ES. Subjective health status in Norwegian patients with Addison’s disease. Clin Endocrinol. 2002;56(5):581–8.
Meyer G, Hackemann A, Penna-Martinez M, Badenhoop K. What affects the quality of life in autoimmune Addison's disease? Horm Metab Res. 2013;45(2):92–5. PubMed
Christiansen JJ, Djurhuus CB, Gravholt CH, Iversen P, Christiansen JS, Schmitz O, et al. Effects of cortisol on carbohydrate, lipid, and protein metabolism: studies of acute cortisol withdrawal in adrenocortical failure. J Clin Endocrinol Metab. 2007;92(9):3553–9. PubMed
Bleicken B, Hahner S, Loeffler M, Ventz M, Decker O, Allolio B, et al. Influence of hydrocortisone dosage scheme on health‐related quality of life in patients with adrenal insufficiency. Clin Endocrinol. 2010;72(3):297–304.
Løvås K, Gjesdal CG, Christensen M, Wolff AB, Almås B, Svartberg J, et al. Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone. Eur J Endocrinol. 2009;160(6):993–1002. PubMed
Björnsdottir S, Sääf M, Bensing S, Kämpe O, Michaelsson K, Ludvigsson JF. Risk of hip fracture in Addison’s disease: a population‐based cohort study. J Intern Med. 2011;270(2):187–95. PubMed
Filipsson H, Monson JP, Koltowska-Häggström M, Mattsson A, Johannsson G. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab. 2006;91(10):3954–61. PubMed
Rushworth RL, Torpy DJ. Modern hydrocortisone replacement regimens in adrenal insufficiency patients and the risk of adrenal crisis. Horm Metab Res. 2015;47(9):637–42. PubMed
Rushworth RL, Torpy DJ. Adrenal insufficiency in Australia: is it possible that the Use of lower dose, short-acting glucocorticoids has increased the risk of adrenal crises? Horm Metab Res. 2015;47(6):427–32. PubMed
Simon N, Castinetti F, Ouliac F, Lesavre N, Brue T, Oliver C. Pharmacokinetic evidence for suboptimal treatment of adrenal insufficiency with currently available hydrocortisone tablets. Clin Pharmacokinet. 2010;49(7):455–63. PubMed
Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61–98. PubMed
Meikle AW, Tyler FH. Potency and duration of action of glucocorticoids: effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function. Am J Med. 1977;63(2):200–7. PubMed
Fietta P. Glucocorticoids and brain functions. Rivista Di Biologia. 2006;100(3):403–18.
Peacey SR, Guo CY, Robinson AM, Price A, Giles MA, Eastell R, et al. Glucocorticoid replacement therapy: are patients over treated and does it matter? Clin Endocrinol. 1997;46(3):255–61.
Howlett TA. An assessment of optimal hydrocortisone replacement therapy. Clin Endocrinol. 1997;46(3):263–8.
Mah PM, Jenkins RC, Rostami‐Hodjegan A, Newell‐Price J, Doane A, Ibbotson V, et al. Weight‐related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clin Endocrinol. 2004;61(3):367–75.
Laureti S, Falorni A, Santeusanio F. Improvement of treatment of primary adrenal insufficiency by administration of cortisone acetate in three daily doses. J Endocrinol Investig. 2003;26(11):1071–5.
Barbetta L, Dall’Asta C, Re T, Libe R, Costa E, Ambrosi B. Comparison of different regimens of glucocorticoid replacement therapy in patients with hypoadrenalism. J Endocrinol Investig. 2005;28(9):632–7.
Ekman B, Bachrach‐Lindström M, Lindström T, Wahlberg J, Blomgren J, Arnqvist HJ. A randomized, double‐blind, crossover study comparing two‐and four‐dose hydrocortisone regimen with regard to quality of life, cortisol and ACTH profiles in patients with primary adrenal insufficiency. Clin Endocrinol. 2012;77(1):18–25.
Alonso N, Granada ML, Lucas A, Salinas I, Reverter J, Oriol A, et al. Evaluation of two replacement regimens in primary adrenal insufficiency patients. Effect on clinical symptoms, health-related quality of life and biochemical parameters. J Endocrinol Investig. 2004;27(5):449–54.
Giordano R, Guaraldi F, Marinazzo E, Fumarola F, Rampino A, Berardelli R, et al. Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison’s disease. Endocrine 2015:1–9.
Mallappa A, Sinaii N, Kumar P, Whitaker MJ, Daley L-A, Digweed D, et al. A phase 2 study of chronocort®, a modified-release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2014;100(3):1137–45. PubMed
Johannsson G, Bergthorsdottir R, Nilsson AG, Lennernas H, Hedner T, Skrtic S. Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. Eur J Endocrinol. 2009;161(1):119–30. PubMed
Øksnes M, Björnsdottir S, Isaksson M, Methlie P, Carlsen S, Nilsen RM, et al. Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone replacement for treatment of Addison's disease: a randomized clinical trial. J Clin Endocrinol Metab. 2014;99(5):1665–74. PubMed
Gagliardi L, Nenke MA, Thynne TR, von der Borch J, Rankin WA, Henley DE, et al. Continuous subcutaneous hydrocortisone infusion therapy in Addison’s disease: a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2014;99(11):4149–57. PubMed
Alkatib AA, Cosma M, Elamin MB, Erickson D, Swiglo BA, Erwin PJ, et al. A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency. J Clin Endocrinol Metab. 2009;94(10):3676–81. PubMed
Hsieh S, White PC. Presentation of primary adrenal insufficiency in childhood. J Clin Endocrinol Metab. 2011;96(6):E925–8. PubMed
Elbelt U, Hahner S, Allolio B. Altered insulin requirement in patients with type 1 diabetes and primary adrenal insufficiency receiving standard glucocorticoid replacement therapy. Eur J Endocrinol. 2009;160(6):919–24. PubMed
Plat L, Leproult R, L’Hermite-Baleriaux M, Fery F, Mockel J, Polonsky KS, et al. Metabolic effects of short-term elevations of plasma cortisol Are more pronounced in the evening than in the morning 1. J Clin Endocrinol Metab. 1999;84(9):3082–92. PubMed
Van Cauter E, Leproult R, Kupfer DJ. Effects of gender and age on the levels and circadian rhythmicity of plasma cortisol. J Clin Endocrinol Metab. 1996;81(7):2468–73. PubMed
Plat L, Byrne MM, Sturis J, Polonsky KS, Mockel J, Fery F, et al. Effects of morning cortisol elevation on insulin secretion and glucose regulation in humans. Am J Physiol. 1996;270(1):E36–42. PubMed
- Recurrent nocturnal hypoglycaemia as a cause of morning fatigue in treated Addison’s disease – favourable response to dietary management: a case report
Kristina S Petersen
R. Louise Rushworth
Peter M Clifton
David J Torpy
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II